BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28738014)

  • 1. Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.
    Yalçınkaya U; Uğraş N; Özgün G; Ocakoğlu G; Deligönül A; Çetintaş SK; Bilgen MS
    Bosn J Basic Med Sci; 2017 Nov; 17(4):302-308. PubMed ID: 28738014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).
    Changchien YC; Tátrai P; Papp G; Sápi J; Fónyad L; Szendrői M; Pápai Z; Sápi Z
    J Transl Med; 2012 Oct; 10():216. PubMed ID: 23110793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.
    Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y
    In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of bcl-2, c-myc, survivin and tumor grade in synovial sarcoma.
    Demır D; Yaman B; Anacak Y; Keçecı B; Kandıloğlu G; Akalin T
    Turk Patoloji Derg; 2014; 30(1):55-65. PubMed ID: 24448706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
    Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
    Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
    Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
    Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.
    Pan YM; Wang CG; Zhu M; Xing R; Cui JT; Li WM; Yu DD; Wang SB; Zhu W; Ye YJ; Wu Y; Wang S; Lu YY
    Mol Cancer; 2016 Dec; 15(1):79. PubMed ID: 27938379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    Alford SH; Toy K; Merajver SD; Kleer CG
    Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
    Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
    World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
    Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
    J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.
    Liu DC; Yang ZL
    Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of EZH2 in gliomas: a meta-analysis.
    Pyo JS; Kang DW
    Int J Biol Markers; 2018 Jan; 33(1):62-67. PubMed ID: 28862715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.
    Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S
    World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis.
    Harms KL; Chubb H; Zhao L; Fullen DR; Bichakjian CK; Johnson TM; Carskadon S; Palanisamy N; Harms PW
    Hum Pathol; 2017 Sep; 67():78-84. PubMed ID: 28739498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
    Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
    Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
    Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
    Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with poor prognosis.
    Peng C; Zhao H; Song Y; Chen W; Wang X; Liu X; Zhang C; Zhao J; Li J; Cheng G; Wu D; Gao C; Wang X
    J Exp Clin Cancer Res; 2017 Oct; 36(1):141. PubMed ID: 29020987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
    Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
    Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.